

Genetic Signatures Appoints Maria Halasz as CEO

Genetic Signatures Limited [ASX:GSS] (“GSS” or the “Company”), a global molecular diagnostics company today announces that its Board of Directors has appointed Maria Halasz as Chief Executive Officer, based in Sydney, Australia.

Ms Halasz brings over 20 years of senior executive, board and capital markets experience, with deep expertise in commercialisation, corporate strategy, corporate development, investor engagement and building international markets, particularly within the life sciences, healthcare and highly regulated sectors.

Ms Halasz has substantial experience leading and engaging with public-market investors, having served for 14 years as Chief Executive Officer and Managing Director of Anagenics Limited (formerly Cellmid Limited, ASX: AN1). During her tenure, she led multiple capital raisings, asset acquisitions, restructures and licensing transactions, working closely with institutional and retail investors.

Ms Halasz is a Graduate of the Australian Institute of Company Directors (GAICD) and currently serves as Non-Executive Director of the Garvan Research Foundation.

Caroline Waldron, Chair of Genetic Signatures commented: “Maria brings a rare combination of leadership, a scientific background, capital markets credibility and deep commercialisation experience, all of which are relevant for the next stage of Genetic Signatures’ growth. Her proven ability to translate innovation into shareholder value, engage effectively with customers, and build sustainable international businesses will be a significant asset to GSS as we execute our growth strategy.”

Maria Halasz, incoming CEO of Genetic Signatures said: “Genetic Signatures has built an exceptional molecular diagnostics platform with growing international relevance. I am excited to bring my experience in commercialisation, strategy and global market development to help the GSS team scale the business, expand its international footprint and translate its innovation into meaningful commercial outcomes.”

Ms Halasz’s appointment as Chief Executive Officer will commence 2 March 2026. Refer to Appendix A for details of Ms Halasz’s remuneration in relation to the appointment as CEO.

Separately, the search process for a permanent Chief Financial Officer continues to progress well.

For further information, see our website (www.geneticsignatures.com) or contact us as below:

Caroline Waldron

Chair Genetic Signatures

caroline.waldron@geneticsignatures.com

Daniel Ireland

Investor Relations

daniel.ireland@datair.com.au

0428 607 884

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics company, specialising in detecting infectious diseases, using patented **3base®** technology to simplify the genetic complexity of pathogen identification. Automated diagnostic workflows accurately screen for multiple infectious pathogens with similar symptoms, in a single test. Genetic Signatures’ unique solutions enable laboratories to enhance diagnostic workflow and efficiencies, while reducing costs. Rapid results support infection control, appropriate patient management and disease surveillance, improving healthcare outcomes. Genetic Signatures continues to expand its global presence with direct representation in Australia, the United States and Europe, alongside international distribution partnerships.

APPENDIX A

The material terms of Ms Halasz’s employment as Chief Executive Officer are summarised below:

KEY TERMS	DETAILS
Appointment and Commencement Date	2 March 2026.
Term	Ms Halasz’s appointment as CEO will commence on the Commencement Date and will continue until terminated in accordance with the Contract.
Base remuneration	Base remuneration of A\$400,000 per annum, exclusive of superannuation.
Short Term Incentive	<p>The short-term incentive (STI) opportunity will be set at 25% of base remuneration for on-target performance, with the ability to increase to 37.5% of base remuneration upon achievement of agreed stretch performance targets, to be determined between Ms Halasz and the Board.</p> <p>No STI will be payable in respect of FY26. Any STI payable for FY27 will be pro-rated to reflect the period of employment during FY26, subject to the achievement of agreed FY27 key performance indicators.</p>
Long Term Incentive	Performance Rights will be granted with a target value equivalent to 40% of base remuneration, with a vesting period of three years, subject to the achievement of long-term service and performance conditions. A stretch outcome of up to 80% of base remuneration may be achieved upon meeting higher performance thresholds.
Termination	Either party may terminate the Contract on 6 months’ notice.